HIRONC

HIRONIC announced on May 15 that it has signed an exclusive supply agreement with EMAGE Medical, a U.S.-based medical device distribution company, for its “next-generation RF combination platform” in the United States.

The agreement will be carried out under an OEM model and will remain valid for two years from May 2026. The contract is also structured to allow an extension through mutual agreement between the two companies.

EMAGE Medical is a medical device distribution company headquartered in Charlotte, North Carolina, and has established specialized medical aesthetic sales channels in the United States. During the contract period, EMAGE Medical plans to supply HIRONIC’s platform device under a locally customized brand, based on its exclusive sales and distribution rights across the U.S. market.

The agreement includes a minimum annual purchase quantity clause. According to the company, this provision is intended to ensure active sales activities by the partner company. At the same time, the agreement includes conditions allowing the minimum purchase obligation to be adjusted in consideration of regulatory changes, including the FDA approval timeline, thereby balancing risk management for both parties.

Based on technical and regulatory cooperation with EMAGE Medical, HIRONIC will support the local brand launch in the United States. The company also plans to build clinical case data and establish a network of key opinion leaders, or KOLs.

The “next-generation RF combination platform” is characterized by the integration of RF, or radiofrequency, and Cold Plasma technologies into a single device. With five types of handpieces, including RF microneedling, Cold Plasma, and Circle monopolar RF, the platform supports a wide range of clinical applications, including skin lifting, tightening, scar and wrinkle improvement, and women’s health.

In particular, the company explained that the sequential combination protocol using RF microneedling and Cold Plasma is designed to enhance collagen activation while minimizing post-procedure inflammation.

A HIRONIC official stated, “This exclusive supply agreement in the United States, the world’s largest medical aesthetic market, demonstrates that our technology has been recognized in the global market.” The official added, “We will continue to strengthen our competitiveness in the medical aesthetic market by enhancing our technological capabilities and expanding strategic partnerships.”

Reporter: Seong-hye Kim, hankyung.com
[shkimmy@hankyung.com]
Translation of the original article
Original article link: https://www.hankyung.com/article/202605158616O​